Next Best Clinical Trial for mCRPC After ARPI Progression
For a man with metastatic castration-resistant prostate cancer who has progressed after androgen-receptor signaling inhibitor therapy, the most appropriate next clinical trial should evaluate 177Lu-PSMA-617 radiopharmaceutical therapy versus cabazitaxel chemotherapy in PSMA-positive patients, or investigate novel combination strategies that address taxane resistance mechanisms.
Primary Recommendation Based on Current Evidence Gaps
The 2025 ASCO guideline 1 identifies a critical knowledge gap: while 177Lu-PSMA-617 shows radiographic progression-free survival benefit in the post-ARPI, post-chemotherapy setting, and emerging data from PSMAfore and SPLASH trials demonstrate efficacy before chemotherapy, there is no head-to-head comparison between 177Lu-PSMA-617 and cabazitaxel in the immediate post-ARPI setting 1. This represents the most clinically relevant unanswered question.
Key Trial Design Elements:
Primary endpoint: Overall survival (not just radiographic PFS), as both PSMAfore and SPLASH failed to show OS benefit, likely due to crossover 1
Population stratification:
- PSMA-positive imaging (mandatory)
- Prior ARPI exposure (abiraterone or enzalutamide)
- Stratify by prior docetaxel in hormone-sensitive setting
- Stratify by disease volume and symptom burden
Control arm: Cabazitaxel (not ARPI switching), as CARD trial established cabazitaxel superiority over second ARPI with OS benefit (13.6 vs 11.0 months, HR 0.64) 1
Alternative High-Priority Trial Designs
1. Biomarker-Directed Combination Strategies
The 2026 literature emphasizes that taxane resistance is biologically heterogeneous and incompletely captured by current biomarkers 2. A trial should:
- Evaluate cabazitaxel combined with targeted agents addressing specific resistance mechanisms (PI3K/AKT/mTOR inhibitors, AR degraders)
- Include mandatory tumor biopsies at progression to identify resistance pathways
- Use adaptive design allowing biomarker-selected cohort expansion
2. Triplet Intensification in Earlier Disease States
Given the shift toward early treatment intensification 3, a critical gap exists in understanding optimal sequencing after progression on ADT + ARPI ± docetaxel triplet therapy. Trial should:
- Enroll patients who progressed specifically after triplet therapy (increasingly common scenario)
- Compare novel mechanisms (PARP inhibitors in HRR-mutated, bispecific T-cell engagers) versus standard cabazitaxel
- Include quality of life as co-primary endpoint given cumulative toxicity concerns
Critical Design Considerations
Avoid Common Pitfalls from Recent Trials:
Crossover contamination: PSMAfore and SPLASH both had ~51% crossover rates, obscuring OS benefit 1. Design must either prohibit crossover or use rank-preserving structural failure time models for analysis.
Inadequate control arms: Many recent trials used ARPI switching as control despite known inferior efficacy 1, 4. Use mechanism-based active comparators.
Selection bias: Trials increasingly enroll highly selected patients, limiting generalizability 5. Include broader eligibility:
- Age >75 years
- ECOG performance status 2
- Moderate renal/hepatic impairment
- Prior radiation to >25% bone marrow
Mandatory Correlative Studies:
Per PCWG3 guidelines 6, trials must include:
- Circulating tumor DNA analysis for AR variants and resistance mutations
- Serial PSMA PET imaging (not just at baseline)
- Patient-reported outcomes using validated instruments
- Bone scan progression documented per 2+2 rule with confirmation scans
Emerging Mechanisms Warranting Investigation
The 2026 evidence highlights several investigational approaches 2, 7:
Highest priority combinations:
- Cabazitaxel + PARP inhibitor (in HRR-mutated subset)
- Cabazitaxel + platinum (exploiting DNA damage synergy)
- AR degraders (avoiding cross-resistance with prior ARPIs)
- Bispecific T-cell engagers targeting PSMA or other prostate antigens
Lower priority (based on systematic review showing minimal benefit 4):
- Checkpoint inhibitor monotherapy (reserve for MSI-H/dMMR only per guideline 1)
- Sequential ARPI therapy (established inferior to cabazitaxel)
Trial Endpoints Aligned with Clinical Outcomes
Following PCWG3 recommendations 6, structure endpoints by disease manifestation:
Primary: Overall survival (mandatory for registration)
Key secondary:
- Radiographic PFS per RECIST 1.1 (nodes/visceral) and bone scan (2+2 rule with confirmation)
- PSA response (≥50% decline from baseline)
- Time to symptomatic progression
- Quality of life (FACT-P or similar)
Exploratory:
- Circulating tumor cell counts
- Pain progression (Brief Pain Inventory)
- Time to first skeletal-related event
Population-Specific Considerations
For post-ARPI, pre-chemotherapy patients: 177Lu-PSMA-617 vs cabazitaxel is the most urgent comparison
For post-ARPI, post-docetaxel patients: Novel mechanisms (AR degraders, bispecifics) vs cabazitaxel or 177Lu-PSMA-617
For HRR-mutated patients: PARP inhibitor combinations vs monotherapy (addressing the PROpel finding of benefit with abiraterone + olaparib in BRCA1/2/ATM mutations 1)
The trial design must acknowledge that real-world treatment patterns show continued second-line ARPI use despite inferior efficacy 1, driven by patient preference and toxicity concerns—making quality of life endpoints particularly critical for changing practice patterns.